Date of Award
College of Business
Type of Degree
Introduction: Neonatal Abstinence Syndrome has been costly for the healthcare system, for every 19 minutes a baby was diagnosed in 2021. Costs and Length of Stay both had been increased for newborns diagnosed. Medically Assisted Treatment for expecting mothers has shown to decrease costs and length of stay for newborns with neonatal abstinence syndrome.
Methodology: This study utilized a literature review and a semi-structured interview. Three databases were used to collect 126 total sources. These sources were reviewed and reduced to 30 total sources that were used in the written research. Of these, 14 sources were used in the results section.
Purpose of the Study: The purpose of this research was to analyze the difference between cost and length of stay for newborns with Neonatal Abstinence Syndrome between mothers who participated in Medication Assisted Treatment (MAT) and those who were in active substance use up to the time of birth with MAT.
Results: The research showed that medically assisted treatment with methadone or buprenorphine during pregnancy decreased costs, length of stay, and severity of symptoms for newborns diagnosed with NAS. Barriers are still present for expectant mothers wanting to receive MAT intervention.
Discussion/Conclusion: Medication Assisted Treatment (MAT) during pregnancy has been shown to have a positive correlation with a shorter initial length of stay for infants with Neonatal Abstinence Syndrome (NAS). The findings show a positive correlation with lower costs for the initial stay of infants whose mother received MAT.
Health services administration.
Health facilities – Business management.
Stanfield, Kimberly and Day, Kylie, "Costs and length of stay associated with treating Neonatal Abstinence Syndrome" (2022). Theses, Dissertations and Capstones. 1709.